Cubist reiterated at outperform by RBC

RBC Capital Markets analyst Jason Kantor reiterated Cubist Pharmaceuticals Inc. at outperform, above average risk. According to the analyst, the primary driver for the company's shares will be ongoing Cubicin sales growth. Fall conferences will help the company leverage its new bacteremia/endocarditis label. Theravance recently reported modestly disappointing top-line results of its phase 3 trials of Telavancin, reducing the competitive threat to Cubist. Shares of the Lexington, Mass.-based biopharmaceutical company were up 12 cents, or 0.51%, at $23.69, on volume of 1,505,186 shares versus the three-month running average of 1,201,140 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.